Exelixis is transforming the challenges of drug development into opportunities to create innovative therapies with significant clinical and commercial potential.

Corporate Profile

Exelixis, Inc., from the Greek word for “evolution,” is a biopharmaceutical company committed to developing and commercializing small molecule therapies with the potential to improve the treatment of cancer.

Over the past decade, we have established a broad development platform, laying the foundation for our continued efforts to bring new therapies for cancer to patients in need. The history of our lead compounMore >>

EXEL (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$17.90
Change (%) Stock is Down 0.12 (0.67%)
Volume2,473,163
Data as of 01/19/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
DateTitle 
01/09/17Update on Dispute between Exelixis and Genentech, a Member of the Roche GroupPrinter Friendly Version
01/03/17Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Printer Friendly Version
12/21/16Exelixis and Ipsen Amend Exclusive Licensing Agreement for the Commercialization and Development of Cabozantinib to Include CanadaPrinter Friendly Version
12/07/16Exelixis Announces Leadership Hires in Public Affairs and Business Development to Support Growth of Company and PipelinePrinter Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Featured Report
Download Documentation2015 Annual Report (pdf)
Download Documentation2014 Annual Report (pdf)

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.